Core 2-MelCore biospecimens

Core 2-MelCore 生物样本

• 批准号: 10208806
• 负责人: JEFFREY E GERSHENWALD
• 金额: $ 22.46万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-16 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10208806
• 关键词: Accounting; Address; Archives; Area; Biological Markers; Biological Specimen Banks; Biopsy; Biostatistics Core; Blood; Cancer Center Support Grant; Cell Line; Cerebrospinal Fluid; Clinical; Clinical Data; Collaborations; Collection; DNA; Data; Data Element; Databases; Detection; Development; Distant Metastasis; Ensure; Evaluation; Fostering; Fresh Tissue; Future; Gene Expression Profiling; Genetic Transcription; Goals; Guidelines; Histologic; Image Analysis; Image Guided Biopsy; Immune; Immunohistochemistry; Immunologics; Infrastructure; Interdisciplinary Study; Laboratories; Lesion; Liquid substance; Lymphocyte Harvest; Measurement; Molecular; Molecular Analysis; Neoplasm Metastasis; Outcome; Pathologic; Pathology; Patient Care; Patients; Performance; Prevention; Primary Neoplasm; Procedures; Process; Prognostic Marker; Proteins; RNA; RNA analysis; Recording of previous events; Recurrence; Research; Research Infrastructure; Research Methodology; Research Personnel; Research Project Grants; Research Support; Resistance; Resources; Sampling; Skin; Specimen; Staging; Standardization; Statistical Data Interpretation; Systemic Therapy; Tissue Banks; Tissue Sample; Tissues; Translating; Translational Research; Tumor-Infiltrating Lymphocytes; University of Texas M D Anderson Cancer Center; Uveal Melanoma; Work; base; clinical database; clinically relevant; disorder prevention; experience; follow-up; human tissue; improved; melanoma; mucosal melanoma; nano-string; novel; novel therapeutic intervention; patient derived xenograft model; predictive marker; programs; prospective; relational database; response; success; therapy resistant; tissue archive; tissue processing; tissue resource; translational impact; treatment strategy; tumor

Core 2: Project Summary/Abstract Over the past 15 years, the primary goal of the MD Anderson SPORE in Melanoma has been to translate our fundamental understanding of melanoma into improved patient care by improving melanoma prevention, detection, and therapy. Building upon this experience and to further this goal, it is essential to continue to conduct high-impact, well-planned, translational research involving well-annotated curated biospecimens and relevant clinical data to identify the pathophysiologic mechanisms of melanoma and the metastatic cascade, identify biomarkers and targets for antitumor therapy, and evaluating the mechanisms of response and resistance in new treatment strategies. The Melanoma Clinical Database, Tissue Resource, and Translational Pathology Core (Core 2) will maintain a comprehensive, prospective, relational database containing detailed clinical, pathologic, and outcome data for patients with melanoma seen and treated at MD Anderson. Core 2 will also procure and process tissue, blood, and cerebrospinal fluid specimens in support of the SPORE Projects, and will facilitate the downstream analysis for histopathologic features, including immunohistochemistry with image analysis and molecular analysis of prospectively collected melanoma specimens as well as archival material. A noteworthy addition for the current SPORE submission is the development and integration of the uveal melanoma database module as well as the addition of an automated request module for sample distribution to facilitate all SPORE-based and other research projects. The current proposal includes expanded efforts and infrastructure to support the optimization of fresh tissue collection and processing of distant metastases from image- guided biopsies, analyte (DNA, RNA, protein) extraction from prospectively collected and archival tissue samples suitable for molecular and immunological interrogation, and the conduct of NanoString gene expression profiling. The samples and/or analytes isolated from biospecimens will be distributed to SPORE projects and other investigators in accordance with our Core operating procedures, and Core 2 will work with each of the SPORE projects, CCSG Cores, collaborator laboratories, and with the Administrative and Biostatistics Cores, to ensure maximum efficiency of tissue/derivatives. Together, Core 2 will be a resource for clinicopathologic data, well-annotated biospecimens, and for optimized acquisition, processing, distribution and analyses that facilitate integration of conventional biomarkers, molecular and immunologic data, with clinicopathologic, treatment, recurrence and follow-up. Overall, these approaches will facilitate the discovery of clinically impactful predictive and prognostic biomarkers, as well as enhanced approaches to anti-tumor therapy across several clinically unmet needs for patients with melanoma. This centralized resource will contribute significantly to the success of the multidisciplinary and translational research projects outlined in this proposal.

核心2：项目摘要/摘要 在过去的15年中，黑色素瘤MD Anderson Spore的主要目标是翻译我们的 通过改善黑色素瘤预防，对黑色素瘤的基本了解改善了患者护理， 检测和治疗。在这一经验并进一步的基础上，必须继续 进行高影响力，精心计划的转化研究 相关的临床数据以确定黑色素瘤和转移性级联的病理生理机制， 确定抗肿瘤疗法的生物标志物和靶标，并评估反应机制和 新治疗策略的抵抗。黑色素瘤临床数据库，组织资源和 翻译病理学核心（核心2）将保持一个全面，前瞻性，关系数据库 包含可见黑色素瘤患者的详细临床，病理和结局数据 在MD Anderson。核心2还将采购和处理组织，血液和脑脊液标本 支持孢子项目，并将促进组织病理学特征的下游分析， 包括免疫组织化学以及前瞻性的图像分析和分子分析 收集的黑色素瘤标本以及档案材料。当前的值得注意的补充 孢子提交也是卵子黑色素瘤数据库模块的开发和整合 作为添加自动请求模块用于样本分布，以促进所有基于孢子的基于孢子和 其他研究项目。当前的建议包括扩大的努力和基础设施 支持优化新鲜组织收集和从图像中的遥远转移加工 指导活检，分析物（DNA，RNA，蛋白）从前瞻性收集的和归档组织中提取 适用于分子和免疫学询问的样品以及纳米串基因的传导 表达分析。从生物测量中分离的样品和/或分析物将分布到 孢子项目和其他调查人员根据我们的核心操作程序以及核心 2将与每个孢子项目，CCSG核心，合作者实验室以及 行政和生物统计学核心，以确保组织/衍生物的最大效率。在一起，核心2 将是临床病理数据，宣布良好的生物测量和优化采集的资源， 处理，分布和分析，促进传统生物标志物，分子和 免疫数据，临床病理学，治疗，复发和随访。总体而言，这些 方法还将促进发现临床上有影响力的预测性和预后生物标志物 作为增强的抗肿瘤疗法的方法，包括 黑色素瘤。这种集中资源将对多学科的成功产生重大贡献 以及本提案中概述的翻译研究项目。